Thymosin Alpha-1: A Comprehensive Drug Review Covering Hepatitis, Cancer, and Immune Enhancement
Thymosin alpha-1 is a synthetic immune-modulating peptide in Phase III trials for hepatitis C and Phase II for hepatitis B, with additional evidence for cancer immunotherapy, HIV, and vaccine enhancement.
Quick Facts
What This Study Found
Thymosin alpha-1 demonstrates clinical efficacy in chronic hepatitis B and C (combined with interferon), with emerging evidence for cancer immunotherapy, HIV, and vaccine enhancement, showing excellent tolerability.
Key Numbers
How They Did This
Comprehensive drug review covering pharmacology (T-cell, NK cell, cytokine modulation), pharmacokinetics (SC dosing, 2-hour half-life), and clinical trial data across hepatitis, cancer, HIV, and vaccine applications.
Why This Research Matters
This review provides the complete clinical picture of thymosin alpha-1 — from mechanism to dosing to efficacy data — serving as the definitive reference for clinical decision-making.
The Bigger Picture
Thymosin alpha-1 represents one of the most clinically advanced peptide immunotherapies. Its broad immune enhancement with minimal side effects positions it as a versatile tool across infectious diseases and cancer.
What This Study Doesn't Tell Us
Clinical data was still accumulating at time of review. Some applications had limited trial sizes. Long-term safety data was emerging. Head-to-head comparisons with newer therapies limited.
Questions This Raises
- ?Will larger Phase III trials confirm hepatitis C efficacy?
- ?Can thymosin alpha-1 enhance checkpoint immunotherapy responses?
- ?What is the optimal combination partner for each indication?
Trust & Context
- Key Stat:
- Phase III Thymosin alpha-1 had reached Phase III clinical trials for hepatitis C, the most advanced stage of any thymic peptide drug development
- Evidence Grade:
- Moderate to strong evidence from a comprehensive review of Phase II/III clinical trial data across multiple indications.
- Study Age:
- Published in 2001. Thymosin alpha-1 (Zadaxin) is now approved in over 30 countries for hepatitis B and as an immune adjuvant.
- Original Title:
- Thymosin alpha-1.
- Published In:
- American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58(10), 879-85; quiz 886-8 (2001)
- Authors:
- Ancell, C D, Phipps, J, Young, L
- Database ID:
- RPEP-00641
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is thymosin alpha-1 used for?
It's approved in many countries for hepatitis B treatment and as an immune enhancer. It's also being studied for hepatitis C, cancer immunotherapy, HIV, and boosting vaccine responses. It works by strengthening T-cell and natural killer cell function.
Is it safe?
Thymosin alpha-1 has an excellent safety profile. Side effects are generally mild — occasional injection site reactions and rarely flu-like symptoms. It doesn't suppress the immune system like many other immune-modulating drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00641APA
Ancell, C D; Phipps, J; Young, L. (2001). Thymosin alpha-1.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 58(10), 879-85; quiz 886-8.
MLA
Ancell, C D, et al. "Thymosin alpha-1.." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha-1." RPEP-00641. Retrieved from https://rethinkpeptides.com/research/ancell-2001-thymosin-alpha1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.